Florian Heitz

23PUBLICATIONS

289CO-AUTHORS

Cancer geneticsCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersSolid tumoursHaematological tumours

Get your video featured.

Publish with JoVE

Get your video featured.

Publish with JoVE

Publications (23)

Sort by Publication Date:

|Jun 12, 2026

Constitutional <i>BRCA1</i> Promoter Methylation in Patients With Ovarian Cancer: Results of the Observational AGO-TR1 Study.

|Dec 03, 2025

Atezolizumab With Bevacizumab and Nonplatinum Chemotherapy for Recurrent Ovarian Cancer: Final Results From the Placebo-Controlled AGO-OVAR 2.29/ENGOT-ov34 Phase III Trial.

Philipp Harter, Frederik Marmé, Andrés Redondo

|Jul 01, 2025

Phase III double-blind randomized placebo controlled trial of atezolizumab in combination with carboplatin and paclitaxel in women with advanced/recurrent endometrial carcinoma: the Asian cohort of the AtTEnd/ENGOT-EN7 trial.

Kenichi Harano, Roldano Fossati, Beatriz Pardo

|Oct 26, 2024

Validation and clinical performance of a single test, DNA based endometrial cancer molecular classifier.

Amy Jamieson, Marcel Grube, Felix Kommoss

|Sep 25, 2024

Impact of metformin, statins, and beta blockers on survival in patients with primary ovarian cancer: combined analysis of four prospective trials of AGO-OVAR and ENGOT/GCIG collaborators.

Dominik Denschlag, Florian Heitz, Jacobus Pfisterer

|Sep 18, 2024

Atezolizumab Combined With Platinum and Maintenance Niraparib for Recurrent Ovarian Cancer With a Platinum-Free Interval >6 Months: ENGOT-OV41/GEICO 69-O/ANITA Phase III Trial.

Antonio González-Martín, María Jesús Rubio, Florian Heitz

Pageof 4

Frequent Collaborators

Philipp Harter

Andreas du Bois

Anna deFazio

Penelope M Webb

Pauline Wimberger

Jalid Sehouli

Susan J Ramus

Paul D P Pharoah

Julie M Cunningham

Jessica N McAlpine

Frequent Collaborators

Philipp Harter

Andreas du Bois

Anna deFazio

Penelope M Webb